CLINICAL TRIALS PROFILE FOR PHENYTOIN
✉ Email this page to a colleague
505(b)(2) Clinical Trials for phenytoin
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| OTC | NCT00011063 ↗ | Effect of Ginkgo Biloba on Phenytoin Elimination | Completed | National Institutes of Health Clinical Center (CC) | Phase 1 | 2001-02-01 | This study will examine how the herbal remedy ginkgo biloba may affect the body's elimination of other medicines. Many people take ginkgo biloba to improve memory, mental alertness and overall feeling of well being. Since this product is considered a food supplement and not a drug, it is not subject to the rigorous pre-market testing required for prescription and over-the-counter (OTC) drugs. As a result, information has not been collected on possible interactions between ginkgo biloba and other medications. This study will look at how ginkgo biloba affects the elimination of phenytoin-a medication used to treat patients with seizures. Normal healthy volunteers 21 years of age or older may be eligible for this 40-day study. Candidates will provide a medical history and undergo a physical examination and routine blood tests. Women of childbearing age must use a reliable form of birth control other than oral contraceptives ("the pill"). For at least 2 weeks before the study and throughout its duration, study participants may not have any of the following: 1) medications that can affect platelet function (e.g., aspirin, Motrin, Advil, Nuprin, ibuprofen, etc.); 2) alcoholic beverages; 3) grapefruit and grapefruit juice; and 4) all medications except those given by study personnel. On day 1 of the study, subjects take one 500-mg dose of phenytoin at 8:00 A.M.. On an empty stomach. (Subjects fast the night before taking the phenytoin and are allowed to eat breakfast 2 hours after the dose). Blood samples are drawn just before dosing and again at 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 32, 48, 72 and 96 hours after the dose. Blood drawn on this first study day is collected through a catheter (small plastic tube) placed in a vein to avoid multiple needlesticks. After the 12-hour sample is collected, the subject goes home and then returns to the clinic for the remaining blood draws, which are taken by direct needlestick. When the blood sampling is completed, subjects begin ginkgo therapy. The NIH Clinical Center provides participants a supply of 60-mg capsules of ginkgo to take twice a day (at 8 A.M. and 8 P.M..) for 4 weeks. At the end of the 4 weeks, subjects are given a second dose of phenytoin as described above and repeat the blood sampling procedure. Subjects continue taking ginkgo during this second phenytoin study. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for phenytoin
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000285 ↗ | Effects of Phenytoin on Cocaine Use in Humans - 2 | Completed | University of Minnesota | Phase 1 | 1996-05-01 | The purpose of this study is to determine the effects of phenytoin on the self-administration of smoked cocaine. |
| NCT00000285 ↗ | Effects of Phenytoin on Cocaine Use in Humans - 2 | Completed | University of Minnesota - Clinical and Translational Science Institute | Phase 1 | 1996-05-01 | The purpose of this study is to determine the effects of phenytoin on the self-administration of smoked cocaine. |
| NCT00000285 ↗ | Effects of Phenytoin on Cocaine Use in Humans - 2 | Completed | National Institute on Drug Abuse (NIDA) | Phase 1 | 1996-05-01 | The purpose of this study is to determine the effects of phenytoin on the self-administration of smoked cocaine. |
| NCT00004403 ↗ | Randomized Study of Albendazole in Patients With Epilepsy Due to Neurocysticercosis | Completed | Johns Hopkins University | N/A | 2000-05-01 | OBJECTIVES: I. Determine the effect of antiparasitic treatment with albendazole on the severity and duration of epilepsy due to neurocysticercosis. II. Determine the effect of a short course of albendazole on Taenia solium cysts present in the brain. III. Determine the natural regression of cerebral T. solium cysts in patients given placebo and their response to treatment at the end of the study. |
| NCT00004817 ↗ | Phase III Double Blind Trial of Valproate Sodium for Prophylaxis of Post Traumatic Seizures | Completed | Harborview Injury Prevention and Research Center | Phase 3 | 1991-02-01 | OBJECTIVES: I. Determine whether treating head injured patients with valproate sodium will reduce the risk of developing seizures as a result of the head injury. II. Determine the safety of valproate, the appropriate dose, and the effect valproate may have on the recovery of the brain's ability to compute numbers, solve problems, remember information, and control the movement of limbs after head injury. |
| NCT00004817 ↗ | Phase III Double Blind Trial of Valproate Sodium for Prophylaxis of Post Traumatic Seizures | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 3 | 1991-02-01 | OBJECTIVES: I. Determine whether treating head injured patients with valproate sodium will reduce the risk of developing seizures as a result of the head injury. II. Determine the safety of valproate, the appropriate dose, and the effect valproate may have on the recovery of the brain's ability to compute numbers, solve problems, remember information, and control the movement of limbs after head injury. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for phenytoin
Condition Name
Clinical Trial Locations for phenytoin
Trials by Country
Clinical Trial Progress for phenytoin
Clinical Trial Phase
Clinical Trial Sponsors for phenytoin
Sponsor Name
